Resona Asset Management Co. Ltd. Sells 14,848 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Resona Asset Management Co. Ltd. cut its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 96.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 479 shares of the medical research company's stock after selling 14,848 shares during the quarter. Resona Asset Management Co. Ltd.'s holdings in Charles River Laboratories International were worth $75,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CRL. Teacher Retirement System of Texas acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $1,231,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Charles River Laboratories International by 15.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock worth $952,000 after purchasing an additional 817 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Charles River Laboratories International by 13.1% during the first quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock worth $6,698,000 after purchasing an additional 5,148 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Charles River Laboratories International by 61.6% during the first quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock worth $210,000 after purchasing an additional 533 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth about $213,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CRL. JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Wall Street Zen lowered Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 17th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $175.69.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares of the company's stock, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 4.5%

CRL traded up $7.0130 during trading on Friday, hitting $161.5530. The company's stock had a trading volume of 1,254,488 shares, compared to its average volume of 971,944. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The stock's fifty day moving average price is $157.67 and its 200-day moving average price is $148.53. The firm has a market capitalization of $7.95 billion, a P/E ratio of -121.47, a PEG ratio of 5.16 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. During the same period in the previous year, the firm earned $2.80 earnings per share. The company's revenue was up .6% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).